NCT04592302

Brief Summary

The purpose of this study is to examine the impact of smoking cessation on total joint arthroplasty patients with respect to perioperative complications and outcomes. The investigators will examine patients who are asked to stop smoking in any manner they choose and also refrain from nicotine replacement therapy, and those who are allowed to continue smoking during the perioperative period for their total knee or total hip replacement.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2016

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

October 13, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 19, 2020

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2021

Completed
Last Updated

October 19, 2020

Status Verified

October 1, 2020

Enrollment Period

4.7 years

First QC Date

October 13, 2020

Last Update Submit

October 16, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Wound healing

    The primary objective of this study is to examine the impact of smoking cessation on total joint arthroplasty patients with respect to combined complications. For the purpose of the study combined complications will include: major in-hospital complications (MI, CVA, PE, pneumonia, return to the operating room, mortality), wound complications, readmission at 90 days, 90-day major complications (MI, CVA, PE, pneumonia, return to the operating room, mortality), and wound complications (prolonged hospitalization due to a wound issue, prolonged drainage \> 7 days, superficial or deep SSI

    3 months

Study Arms (2)

Smoking Cessation Group

participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)

Diagnostic Test: Blood Draw

Smoker Group 2

participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period

Diagnostic Test: Blood Draw

Interventions

Blood DrawDIAGNOSTIC_TEST

2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body

Smoker Group 2Smoking Cessation Group

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are current smokers having surgery for total joint arthroplasty at Rothman Orthopaedic Institute

You may qualify if:

  • Primary elective total joint arthroplasty patients undergoing surgery with a Rothman Institute arthroplasty surgeon.
  • Participant is a current smoker.
  • Diagnosis of osteoarthritis, inflammatory arthritis, and post-traumatic arthritis.
  • Age \< 18
  • Revision surgery
  • Prior infection in hip or knee at the surgical site
  • BMI \>40 (It is currently the standard of care in our practice to require patients to have a BMI \< 40 due to an increased risk of infection. This will not represent a change in practice.)
  • Diabetics with Hgb A1C \>8 (It is currently the standard of care in our practice to require patients to have a Hgb A1C \<8 due to an increased risk of infection. This will not represent a change in practice.)
  • Patients using chewing tobacco, cigars, or other form of oral tobacco product
  • Patients using e-cigarettes or vaporizers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rothman Orthopaedic Institute

Philadelphia, Pennsylvania, 19107, United States

Location

MeSH Terms

Conditions

Smoking

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 13, 2020

First Posted

October 19, 2020

Study Start

December 1, 2016

Primary Completion

July 31, 2021

Study Completion

July 31, 2021

Last Updated

October 19, 2020

Record last verified: 2020-10

Locations